Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: A study of 45 cases

Human Pathology

Volumn 44, Issue 5, 2013, Pages 860-866

  Oliva, Esther ^a   Pinheiro, Nathanael F ^a   Heney, Niall M ^a   Kaufman, Donald S ^a   Shipley, William U ^a   Gurski, Carol ^a   Spicer, Beverly ^a   Paner, Gladell P ^b   Gown, Allen M ^c   Amin, Mahul B ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c PHENOPATH LABORATORIES   (United States)

Author keywords

CD44s; CK20; Differential diagnosis; p53; Radiation changes; Urothelial carcinoma in situ

Indexed keywords

ANTIGEN; CD44S ANTIGEN; CYTOKERATIN 20; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CARCINOMA IN SITU; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; RADIATION INDUCED ATYPIA; RADIATION INJURY; TRANSITIONAL CELL CARCINOMA;

ANTIGENS, CD44; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; NEOPLASMS, RADIATION-INDUCED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84876484267     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.08.011     Document Type: Article

References (35)

1. J.I. Epstein, M.B. Amin, V.R. Reuter, and F.K. Mostofi The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee Am J Surg Pathol 22 1998 1435 1448 (Pubitemid 28550639)
2. N. Nese, R. Gupta, M.H. Bui, and M.B. Amin Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis J Natl Compr Canc Netw 7 2009 48 57
3. L. Cheng, J.C. Cheville, and R.M. Neumann Survival of patients with carcinoma in situ of the urinary bladder Cancer 85 1999 2469 2474 (Pubitemid 29244858)
4. S.F. Shariat, G.S. Palapattu, and P.I. Karakiewicz Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy Eur Urol 51 2007 152 160 (Pubitemid 44821530)
5. D.S. Kaufman, W.U. Shipley, and P.P. Griffin Selective bladder preservation by combination treatment of invasive bladder cancer N Engl J Med 329 1993 1377 1382 (Pubitemid 23317347)
6. W.U. Shipley, D.S. Kaufman, and E. Zehr Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer Urology 60 2002 62 67 [discussion 67-68] (Pubitemid 34722947)
7. C. Weiss, M. Wittlinger, and D.G. Engehausen Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy Int J Radiat Oncol Biol Phys 70 2008 1502 1506 (Pubitemid 351417749)
8. A.L. Zietman, J. Grocela, and E. Zehr Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder Urology 58 2001 380 385 (Pubitemid 32816355)
9. P.M. Baker, and R.H. Young Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: a report of 4 cases Hum Pathol 31 2000 678 683 (Pubitemid 30445470)
10. T.Y. Chan, and J.I. Epstein Radiation or chemotherapy cystitis with "pseudocarcinomatous" features Am J Surg Pathol 28 2004 909 913 (Pubitemid 38856847)
11. A. Lopez-Beltran, R.J. Luque, R. Mazzucchelli, M. Scarpelli, and R. Montironi Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer J Clin Pathol 55 2002 641 647 (Pubitemid 34970083)
12. J.K. McKenney, S. Desai, C. Cohen, and M.B. Amin Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens Am J Surg Pathol 25 2001 1074 1078 (Pubitemid 32685906)
13. R. Moll, A. Lowe, J. Laufer, and W.W. Franke Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies Am J Pathol 140 1992 427 447
14. C. Mallofre, M. Castillo, V. Morente, and M. Sole Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia Mod Pathol 16 2003 187 191 (Pubitemid 36337422)
15. A.S. Sarkis, G. Dalbagni, and C. Cordon-Cardo Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder J Urol 152 1994 388 392 (Pubitemid 24221226)
16. S.F. Shariat, J. Kim, G. Raptidis, G.E. Ayala, and S.P. Lerner Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder Urology 61 2003 1140 1145 (Pubitemid 36693989)
17. H. Tashiro, C. Isacson, and R. Levine p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis Am J Pathol 150 1997 177 185 (Pubitemid 27027108)
18. K.B. Hodges, A. Lopez-Beltran, D.D. Davidson, R. Montironi, and L. Cheng Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features Hum Pathol 41 2010 155 162
19. M. Yin, S. Bastacky, A.V. Parwani, T. McHale, and R. Dhir p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ Hum Pathol 39 2008 527 535
20. W. Sun, P.L. Zhang, and G.A. Herrera p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder Appl Immunohistochem Mol Morphol 10 2002 327 331 (Pubitemid 35453691)
21. H. Yin, Q. He, T. Li, and A.S. Leong Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium Appl Immunohistochem Mol Morphol 14 2006 260 265 (Pubitemid 44319050)
22. S. Desai, S.D. Lim, and R.E. Jimenez Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia Mod Pathol 13 2000 1315 1323 (Pubitemid 32014669)
23. P. Harnden, N. Mahmood, and J. Southgate Expression of cytokeratin 20 redefines urothelial papillomas of the bladder Lancet 353 1999 974 977 (Pubitemid 29132607)
24. A. Alsheikh, Z. Mohamedali, E. Jones, J. Masterson, and C.B. Gilks Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology Mod Pathol 14 2001 267 272 (Pubitemid 32298910)
25. I.Z. Yildiz, R. Recavarren, and H.B. Armah Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies Diagn Pathol 4 2009 35
26. D. Lohmann, C. Ruhri, M. Schmitt, H. Graeff, and H. Hofler Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives Diagn Mol Pathol 2 1993 36 41 (Pubitemid 23197496)
27. M. Gallucci, F. Guadagni, and R. Marzano Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters J Clin Pathol 58 2005 367 371 (Pubitemid 40516166)
28. G.R. Screaton, M.V. Bell, J.I. Bell, and D.G. Jackson The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat J Biol Chem 268 1993 12235 12238 (Pubitemid 23182367)
29. S. Goodison, V. Urquidi, and D. Tarin CD44 cell adhesion molecules Mol Pathol 52 1999 189 196 (Pubitemid 29369203)
30. J. Kuncova, M. Urban, and V. Mandys Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells APMIS 115 2007 1194 1205 (Pubitemid 350293946)
31. J.S. Ross, A.D. del Rosario, and H.X. Bui Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma Mod Pathol 9 1996 854 860 (Pubitemid 26279277)
32. N.E. Stavropoulos, I. Filliadis, and E. Ioachim CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors Int Urol Nephrol 33 2001 479 483
33. V. Toma, D. Hauri, and U. Schmid Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma Am J Pathol 155 1999 1427 1432
34. A.C. Woodman, S. Goodison, M. Drake, J. Noble, and D. Tarin Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia Clin Cancer Res 6 2000 2381 2392 (Pubitemid 30399206)
35. S. Russo, G. Botti, and P. Vinaccia A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens Pathologica 99 2007 46 49 (Pubitemid 350186359)